New York Life Investment Management LLC Buys 59,935 Shares of Lantheus Holdings, Inc. $LNTH

New York Life Investment Management LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 59,935 shares of the medical equipment provider’s stock, valued at approximately $5,965,000. New York Life Investment Management LLC owned approximately 0.09% of Lantheus at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ABS Investment Management LLC acquired a new stake in Lantheus in the second quarter worth about $232,974,000. Western Wealth Management LLC purchased a new stake in shares of Lantheus during the first quarter worth about $25,000. USA Financial Formulas purchased a new stake in shares of Lantheus during the third quarter worth about $41,000. Allworth Financial LP acquired a new position in shares of Lantheus during the second quarter valued at about $49,000. Finally, Bessemer Group Inc. increased its holdings in shares of Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 354 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on LNTH shares. Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and decreased their price objective for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Weiss Ratings lowered shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, October 15th. Finally, Leerink Partners set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $107.44.

Lantheus Stock Performance

Shares of LNTH opened at $101.25 on Friday. The stock has a 50-day moving average of $100.31 and a two-hundred day moving average of $92.74. Lantheus Holdings, Inc. has a one year low of $51.47 and a one year high of $111.86. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.06 and a current ratio of 3.25. The stock has a market cap of $6.62 billion, a P/E ratio of 18.75 and a beta of 0.01.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.45. The business had revenue of $389.91 million for the quarter, compared to the consensus estimate of $355.74 million. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.27 EPS. As a group, research analysts predict that Lantheus Holdings, Inc. will post 4.54 EPS for the current year.

Lantheus Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.